WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Earnings & Revenue

DMAC past revenue growth

How has DMAC's revenue growth performed historically?
Company
N/A
Industry
165.61%
Market
17.84%
DMAC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
DMAC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

DMAC earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$19.3M
Current Profit Margin
0%

DMAC Return on Equity

Current Company
-39.9%
Current Industry
-63.6%
Current Market
188%
DMAC's Return on Equity (-39.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when DMAC announces earnings.

DMAC Return on Assets

Current Company
-37.7%
Current Industry
3%
DMAC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

DMAC Return on Capital Employed

Current Company
-37.49%
Current Industry
19.6%
DMAC has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DMAC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
DMAC$0.00-$19.16M-$19.30M-100.00%N/A
RNAC$26.00M-$233.28M-$219.71M+95.83%N/A
ATHA$0.00-$116.49M-$117.67MN/AN/A
VINC$0.00-$47.95M-$48.85MN/AN/A
VANI$0.00-$24.39M-$25.65M-100.00%N/A

DMAC earnings dates

Next earnings date
May 13, 2024

Diamedica Therapeutics Earnings & Revenue FAQ

What were DMAC's earnings last quarter?

On Invalid Date, Diamedica Therapeutics (NASDAQ: DMAC) reported Q4 2023 earnings per share (EPS) of -$0.14, up 0% year over year. Total Diamedica Therapeutics earnings for the quarter were -$5.03 million. In the same quarter last year, Diamedica Therapeutics's earnings per share (EPS) was -$0.14.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.

What was DMAC's earnings growth in the past year?

As of Q1 2024, Diamedica Therapeutics's earnings has grown year over year. Diamedica Therapeutics's earnings in the past year totalled -$19.30 million.

What is DMAC's earnings date?

Diamedica Therapeutics's earnings date is Invalid Date. Add DMAC to your watchlist to be reminded of DMAC's next earnings announcement.

What was DMAC's revenue last quarter?

On Invalid Date, Diamedica Therapeutics (NASDAQ: DMAC) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Diamedica Therapeutics's revenue was $0.00.

What was DMAC's revenue growth in the past year?

As of Q1 2024, Diamedica Therapeutics's revenue has grown null year over year. Diamedica Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.